{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"20","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence including but not limited to skin rash, elevated liver function tests, nausea/vomiting/diarrhea.","groups":[{"description":"patients receiving transplant using ATG/Bu/Flu/Cy per this protocol and who had severe graft versus host disease as a post-transplant complication","id":"OG000","title":"Severe Graft Versus Host Disease"}],"paramType":"NUMBER","populationDescription":"23 patients were able to be analyzed for severe gvhd","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease","type":"SECONDARY","unitOfMeasure":"participants"}